Scientific editorial illustration of a C15:0 odd-chain fatty acid crossing from food and plasma into a human-trial evidence scale, with cohort associations separated from causal results
Geroprotect Blog

Geroprotect research note · Evidence review

Pentadecanoic Acid (C15:0): Human Trials, Essentiality and Causal Limits

Two short randomised trials, favourable but non-causal epidemiology, commercially concentrated mechanisms and the exact 240 mg formula boundary

Abstract

Pentadecanoic acid (C15:0) is a naturally occurring 15-carbon saturated fatty acid found in dairy fat, ruminant foods and some fish, and produced to a limited extent through endogenous odd-chain-fatty-acid pathways. Its biology is credible; its marketing has moved faster than its human evidence.

Two 12-week randomised trials have tested supplemental C15:0. A 30-person pilot at 200 mg/day established that supplementation can raise plasma C15:0 and found a group-level reduction in gamma-glutamyl transferase (GGT), but no other significant group-level secondary outcome. A separate 88-person trial embedded 300 mg/day within a calorie-restricted Mediterranean-like diet: both diet groups reduced liver fat and weight, with no significant incremental C15:0 effect on those outcomes; LDL cholesterol and several microbiome-composition signals differed between the two diet arms. Large cohorts associate higher circulating C15:0 with lower cardiometabolic risk, but those measurements are also markers of diet and metabolism. A 2026 observational-plus-Mendelian-randomisation study found modest blood-pressure associations but no support for a causal cardiovascular effect.

Calling C15:0 an essential fatty acid remains a hypothesis. No authoritative dietary reference intake, validated human deficiency syndrome or clinically accepted blood threshold has been established. Geroprotect Essentials II lists 240 mg of Pentadecanoic Acid (C15:0) per full six-tablet labelled serving. No trial has tested that amount, Essentials II, the combined formulas, or any proposed stack synergy.

01 · Identity and essentiality

An odd-chain fatty acid—not yet an essential nutrient

Pentadecanoic acid is written C15:0 because it has fifteen carbon atoms and no carbon–carbon double bonds. Unlike the more abundant even-chain saturated fatty acids, its final round of mitochondrial beta-oxidation can yield six acetyl-CoA molecules and one three-carbon propionyl-CoA. Propionyl-CoA can be converted through methylmalonyl-CoA into succinyl-CoA, a TCA-cycle intermediate. C15:0 can also be incorporated into complex lipids and can undergo elongation or desaturation in experimental human-cell systems.6

That is established metabolic chemistry, but it does not show that 240 mg of oral C15:0 increases TCA-cycle flux in a human target tissue or improves mitochondrial function. The body also has routes that can contribute to odd-chain fatty acids, including alpha-oxidation of even-chain fatty acids and propionate-linked synthesis under particular conditions. Diet is an important determinant of circulating C15:0; it is not necessarily the only determinant.

What “essential” would need to mean

An essential nutrient is not defined simply by having biological activity or by being associated with health. A persuasive case requires inadequate endogenous supply, a reproducible deficiency state and correction of that state by the nutrient. Current US dietary references provide adequate intakes for linoleic acid and alpha-linolenic acid; the National Institutes of Health identifies those two as essential fatty acids. Neither source establishes a requirement or intake reference for C15:0.78

A 2024 academic mini-review described C15:0 essentiality as controversial. It argued that dietary intake may be important and that several proposed criteria could be met, while also stating that nutritional deficiency studies are still needed. The review cautioned that many striking cell results came from one research team using the same high-throughput platform and require confirmation.6 The accurate position is therefore “plausible and unresolved,” not “debunked” and not “the first essential fatty acid in 90 years.”

The terms “Cellular Fragility Syndrome” and an “optimal” circulating range above roughly 0.4%–0.64% were proposed in a single-author review by a Seraphina Therapeutics and Epitracker founder. They are useful hypotheses to test, but they are not recognised diagnoses, validated deficiency thresholds or treatment targets.9

02 · Controlled human evidence

Two short trials, with two different questions

The UCSD pilot: exposure first, exploratory outcomes second

Robinson and colleagues randomised 30 adults aged 18–25 with overweight or obesity in a 2:1 ratio to 200 mg/day of free-fatty-acid C15:0 or rice-flour placebo for 12 weeks. Participants took two 100 mg capsules each morning. The study was powered for its primary outcome—change in plasma C15:0—not for liver enzymes, lipids, glucose, inflammation, haemoglobin or clinical events.1

Plasma C15:0 increased by an adjusted 2.07 µg/mL more than placebo, although individual changes in the active group ranged from −1.21 to 5.31 µg/mL. GGT was the only significant group-level secondary outcome, with an adjusted difference of −11 U/L relative to placebo. No other secondary endpoint changed significantly between the randomised groups.

The frequently quoted ALT, AST and haemoglobin findings came from an exploratory analysis after the active group was split into ten participants who ended above a proposed 5 µg/mL threshold and ten who did not. The higher-level subgroup had larger median changes in those markers, but it also had higher adherence—95.0% versus 84.3%—and the trial was not powered to validate the threshold. This is a signal for a prospectively stratified trial, not proof of a responder class or a clinical target.

No significant adverse events occurred during the 12 weeks. The project received NIH support and support from Seraphina Therapeutics, which supplied C15:0 and placebo. The authors reported one investigator’s grants to UCSD from Intercept and Genfit and otherwise no conflicts. That disclosure does not erase the randomisation; it does make independent replication valuable.

TANGO: a diet trial with an incremental C15:0 comparison

The TANGO trial randomised 88 Chinese Singaporean women aged 21–45 with fatty liver disease to one of three 12-week programmes: a calorie-restricted Asian-adapted Mediterranean-like diet plus 300 mg/day C15:0 (n=31), the same diet plus placebo (n=28), or standard hypocaloric advice without study meals (n=29). The two intensive-diet groups received frozen meals and daily soymilk; C15:0 or placebo was incorporated into the soymilk.2

Liver proton-density fat fraction fell by 32.6%, 30.1% and 10.3% in the C15:0 diet, placebo diet and control groups, respectively. Weight also fell more in both intensive-diet groups than in control. Crucially, liver fat and weight did not differ significantly between the C15:0 and placebo versions of the diet. The sample-size calculation was oriented to the diet-versus-control contrast, not a definitive incremental C15:0 effect.

Among measured cardiometabolic outcomes, LDL cholesterol declined more with C15:0 than with the otherwise matched diet. The microbiome analysis also found increased abundance of Bifidobacterium adolescentis and reduced abundance of Bacteroides dorei and Bacteroides stercoris; the clinical meaning of those compositional signals is unknown. Blood pressure, insulin, HOMA-IR and HbA1c did not show a distinct C15:0 advantage, and the paper reported no other differences between the two intensive-diet arms.

The C15:0 arm began with lower liver fat than the placebo-diet arm—12.4% versus 15.7%. The authors therefore warned that the numerical difference in the proportion reaching less than 5% liver fat could not establish a supplement effect. No adverse effects were reported. Funding came through Singapore’s A*STAR Industry Alignment Fund; study food and soymilk involved Wilmar International and several authors were affiliated with the WIL@NUS Corporate Laboratory. The authors declared no relevant conflicts, and the paper disclosed no Seraphina role.

03 · Observational versus causal evidence

A favourable biomarker can still be a passenger

The observational record is substantial. In a harmonised analysis of 16 prospective cohorts from 12 countries, 63,682 participants contributed 15,180 incident type 2 diabetes cases over an average nine years. A cohort-specific 10th-to-90th-percentile difference in C15:0 was associated with a hazard ratio of 0.80 for incident diabetes. The authors explicitly retained residual confounding and inability to separate food sources as limitations.3

In a Swedish cohort of 4,150 older adults, each interquartile-range increase in serum C15:0 was associated with lower incident cardiovascular disease, while all-cause mortality showed a non-linear, U-shaped pattern and no significant linear association after full adjustment. The same report’s meta-analysis of prospective studies found lower cardiovascular risk at higher dairy-fat biomarker levels.4 These are important population signals, but they concern circulating biomarkers—not random assignment to pure C15:0.

Circulating C15:0 reflects dairy fat, some other foods, absorption, lipid turnover and endogenous metabolism. People with higher values can also differ in physical activity, smoking, adiposity, socioeconomic factors and the foods that delivered the fatty acid. Statistical adjustment reduces known confounding; it cannot guarantee that the molecule itself caused the outcome.

The 2026 causal stress test

Steffen and colleagues examined 3,196 Black and White CARDIA participants and replicated selected associations in 3,889 White ARIC participants. Higher plasma C15:0 was associated with modestly lower systolic and diastolic blood pressure and an incident-hypertension hazard ratio of 0.86 in both cohorts. It was not associated with incident cardiovascular disease or cardiac structure and function.5

A nine-variant Mendelian-randomisation instrument, explaining about 2.5% of C15:0 variance, did not support causal effects on blood pressure, resting heart rate or hypertension. The null result is not proof that every possible C15:0 effect is zero: the genetic analysis was ancestry-limited and cannot exclude small effects or effects on untested outcomes. It does, however, weaken the claim that favourable cardiovascular cohort associations already demonstrate a direct, clinically meaningful supplement benefit. The authors reported no commercial or financial conflict.

04 · Mechanisms and evidence tiers

Interesting pathways, different standards of proof

ClaimWhat the evidence establishes
Odd-chain beta-oxidationC15:0 can yield acetyl-CoA and propionyl-CoA; propionyl-CoA can enter an anaplerotic pathway to succinyl-CoA. This is biochemistry, not a demonstrated 240 mg mitochondrial outcome.
AMPK and glucose uptakeC15:0 increased basal and insulin-stimulated glucose uptake through an AMPK-linked pathway in C2C12 mouse muscle cells. Human glucose endpoints have not shown a distinct supplement effect.
PPAR, mTOR and inflammatory signalsCell and animal studies report pathway activity and biomarker changes. They do not establish disease prevention, rapamycin equivalence or healthy-aging efficacy in people.
Membrane stability and ferroptosisA saturated lipid is less directly peroxidisable than a polyunsaturated lipid, and C15:0 can enter membranes. A C15:0 deficiency syndrome or anti-ferroptosis benefit has not been demonstrated in humans.
Pentadecanoylcarnitine signallingA C15:0 metabolite activated cannabinoid, serotonin and histamine receptor assays and rose in dolphins after a modified fish diet. No human mood, sleep, pain or allergy outcome follows from those assays.

An independent cell study found that C15:0 increased glucose uptake in C2C12 myotubes through AMPK–AS160 signalling.13 Separate studies describe PPAR-alpha/delta activity, HDAC6 inhibition, altered inflammatory biomarkers, mitochondrial-superoxide signals and mTOR-related phenotypes. These findings help prioritise experiments. They do not show that oral C15:0 changes those pathways in human tissue at the current formula amount.

The most expansive comparisons came from BioMAP panels commissioned by commercially connected investigators. C15:0 altered biomarkers across twelve primary-human-cell systems and shared some assay patterns with EPA, rapamycin, metformin and acarbose.1112 Similarity in a multi-cell assay is not equivalent potency, safety or clinical benefit. “Broader and safer than omega-3” and “rapamycin-like” are therefore cell-platform descriptions, not human comparative conclusions.

Pentadecanoylcarnitine activated CB1, CB2, 5-HT1A, 5-HT1B, H1 and H2 receptor assays at micromolar concentrations.14 The work used cell assays and a modified fish-diet study in dolphins; it did not establish that oral C15:0 creates relevant human exposure in the brain or improves pain, mood, sleep or allergy.

Why metabolic adjacency is not stack synergy

Conversion of propionyl-CoA to succinyl-CoA uses biotin- and vitamin-B12-dependent enzymes. The source dossiers turned that dependency into a claim that the Geroprotect stack supplies biotin, B12, pantothenate and a methyl-donor layer. It does not. The current 26-active formula does not list vitamin B12, biotin, pantothenate, riboflavin, magnesium, trimethylglycine, methylfolate, lipoic acid, apolactoferrin, vitamin C, iron or carnitine.

Ca-AKG and Coenzyme Q10 are in Essentials I, not in the same bottle as C15:0. No direct experiment has shown that C15:0 works better with either ingredient, with NR, or with any Essentials II active. Nor has a trial shown a combined membrane, ferroptosis, TCA-cycle or NAD+ benefit. Biochemical proximity can justify a study; it cannot justify a synergy claim.

05 · Commercial influence

The evidence is not all from the same place

The foundational 2020 paper combined epidemiology, cell assays and animal work to argue that C15:0 could be essential. It disclosed that its lead author co-founded and worked for Epitracker and Seraphina Therapeutics, which financed work in the paper and held exclusive US Navy licences to commercialise odd-chain fatty acids. Other authors disclosed company-funded work, advisory roles or equity.10

The 2022 BioMAP comparison and 2023 longevity-compound comparison were also authored by Seraphina founders or employees and used the company’s FA15 material; patent and licensing interests were disclosed.1112 The “Cellular Stability Hypothesis” review was authored by the same commercial founder.9

Commercial participation does not make a result false. It changes how much weight should rest on independent replication, prespecified endpoints and transparent negative findings. The UCSD pilot had Seraphina support but academic investigators and a declared primary endpoint. TANGO did not disclose Seraphina involvement, although it had industry-linked food-production infrastructure. The 2026 CARDIA/ARIC analysis was federally supported and commercially independent. Reading these streams together is more informative than accepting or dismissing any one of them by affiliation alone.

06 · Absorption, safety and regulation

Short-term reassurance without an invented certainty

A 2013 malabsorption-test study gave 15 healthy adults 2.5 g of free pentadecanoic acid in a 550-kcal, 32-g-fat test meal, alongside a triglyceride tracer. Orlistat reduced absorption of the triglyceride-derived tracer but not the free-fatty-acid control.15 This supports absorption of a free fatty acid without pancreatic-lipase hydrolysis in that test. It does not establish near-100% absolute bioavailability at 100–300 mg, a universal “1 µg/mL per 100 mg” rule, or a requirement to take C15:0 with a fatty meal.

In the UCSD trial, 200 mg/day produced no significant adverse events over 12 weeks; in TANGO, no adverse effects were reported at 300 mg/day over 12 weeks. Those findings are reassuring for the studied products, populations and durations. With 30 and 88 randomised participants, they cannot estimate rare events, long-term safety, pregnancy or breastfeeding, use in older or medically complex adults, or interactions with medicines and a 13-active formula. No formal tolerable upper intake level for supplemental C15:0 has been established.

The US Food and Drug Administration’s food-substance inventory lists pentadecanoic acid as a flavouring agent or adjuvant under FEMA 4334 and a FEMA GRAS publication.16 That listing is not FDA approval of a C15:0 supplement, a disease claim, chronic use, the Essentials II finished product or use during pregnancy. The source dossiers’ unqualified “GRAS” statement therefore needs a narrower regulatory description.

No reviewed human study establishes a special timing window, cycling schedule, blood target or self-testing protocol. People who are pregnant or breastfeeding, have a medical condition, or use medicines should follow the current product label and obtain individual clinical or pharmacy guidance for the complete formula. This is a proportionate evidence boundary, not evidence that C15:0 commonly causes harm.

07 · Formula context

What 240 mg in Essentials II does—and does not—mean

A full six-tablet labelled serving of Geroprotect Essentials II contains 240 mg of Pentadecanoic Acid (C15:0). That amount sits numerically between the 200 mg UCSD pilot and the 300 mg TANGO intervention. Numerical proximity is not dose-response evidence: neither trial tested 240 mg, the Essentials II delivery matrix, the other twelve ingredients in the bottle or the combined Essentials I and II system.

The current document intake includes a supplier raw-material certificate for batch XJYPA250516 reporting 99.1% by gas chromatography. It remains a candidate raw-material record pending issuer verification and finished-lot traceability. A supplier COA cannot establish the C15:0 amount, dissolution, stability or exposure of a current finished Essentials II batch.

The defensible rationale is modest: C15:0 is absorbed; one small trial found a GGT signal; a second found incremental LDL and microbiome-composition signals; epidemiology is generally favourable; and several mechanisms merit further testing. The equally important limit is that no trial has shown that Essentials II improves liver disease, cardiovascular outcomes, metabolic health, biological aging, healthspan or lifespan.

StatementEvidence boundary
C15:0 is an essential fatty acidNot established. The hypothesis has biological arguments, but no accepted human deficiency syndrome or dietary requirement.
C15:0 improves liver markersNarrow signal. GGT changed at group level in a 30-person pilot; ALT and AST came from an exploratory threshold subgroup. TANGO did not show an incremental liver-fat effect.
Higher C15:0 prevents diabetes or cardiovascular diseaseNot demonstrated. Cohort associations are favourable, but supplement causality and event reduction have not been established; cardiovascular Mendelian-randomisation results were null.
C15:0 is rapamycin-like or safer than omega-3Cell-assay comparisons only, from commercially connected research. There is no clinical head-to-head evidence.
The Geroprotect stack supplies all C15:0 cofactorsIncorrect. Several named vitamins and minerals are not among the current 26 actives, and no formula synergy has been tested.
240 mg is a validated longevity doseUnproven. It is the current labelled amount in Essentials II, not an established therapeutic or longevity dose.

Questions

Frequently asked questions

What is Pentadecanoic Acid (C15:0)?

It is a 15-carbon odd-chain saturated fatty acid present in several foods and at low levels in human lipids. It can be incorporated into complex lipids or broken down into acetyl-CoA and propionyl-CoA. Those metabolic roles do not by themselves establish a supplement benefit.

Is C15:0 officially an essential fatty acid?

No authoritative dietary requirement or recognised human deficiency syndrome has been established. Researchers disagree about whether C15:0 may eventually meet essentiality criteria. “Potential essential fatty acid” is accurate; presenting the classification as settled is not.

Have human randomised trials tested C15:0?

Yes. A 30-person, 12-week trial at 200 mg/day primarily showed increased plasma C15:0 and found a secondary GGT signal. An 88-person, 12-week diet trial at 300 mg/day found incremental LDL and microbiome-composition signals but no C15:0-specific advantage for liver fat or weight. Neither tested healthy aging or clinical events.

Is 5 µg/mL a validated blood target?

No. It was a proposed threshold used in an exploratory analysis of one small trial. The subgroup above it also had better adherence, and no prospective trial has validated it as an optimal concentration, deficiency cut-off or treatment target.

Does 240 mg reproduce the trial results?

That has not been tested. The current Essentials II amount is between the two trial amounts, but the products, matrices, participants and outcomes differ. Effects cannot be interpolated by milligrams alone.

Does C15:0 work synergistically with NR, Ca-AKG or CoQ10?

No direct human or component-controlled experiment has established those combinations. NR is in Essentials II; Ca-AKG and Coenzyme Q10 are in Essentials I. Metabolic pathways can intersect without producing a clinically meaningful supplement synergy.

Is supplemental C15:0 safe?

The two 12-week trials were reassuring at 200 and 300 mg/day, with no significant adverse events in the UCSD trial and no adverse effects reported in TANGO. The evidence is still too small and short to establish rare-event, long-term, pregnancy or broad medication safety, especially for a multi-ingredient finished formula.

Has Essentials II been clinically tested?

No controlled human trial has tested Essentials II, its 240 mg C15:0 serving, both Geroprotect formulas together, or their proposed effects on liver markers, cardiovascular outcomes, aging or lifespan.

Sources

References

  1. Robinson MK, et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. Journal of Nutrition. 2024;154:2763–2771. DOI 10.1016/j.tjnut.2024.07.030.
  2. Chooi YC, et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. American Journal of Clinical Nutrition. 2024;119:788–799. DOI 10.1016/j.ajcnut.2023.11.013.
  3. Imamura F, et al. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies. PLoS Medicine. 2018;15:e1002670. DOI 10.1371/journal.pmed.1002670.
  4. Trieu K, et al. Biomarkers of dairy fat intake, incident cardiovascular disease, and all-cause mortality: a cohort study, systematic review, and meta-analysis. PLoS Medicine. 2021;18:e1003763. DOI 10.1371/journal.pmed.1003763.
  5. Steffen BT, et al. Plasma pentadecanoic acid is modestly related to cardiovascular health in CARDIA and ARIC cohorts: observational associations without evidence of causality. Frontiers in Nutrition. 2026;13:1720975. DOI 10.3389/fnut.2026.1720975.
  6. Ciesielski V, et al. New insights on pentadecanoic acid with special focus on its controversial essentiality: a mini-review. Biochimie. 2024;227:123–129. DOI 10.1016/j.biochi.2024.10.008.
  7. National Institutes of Health, Office of Dietary Supplements. Omega-3 Fatty Acids: Health Professional Fact Sheet. Accessed 14 July 2026.
  8. National Academies of Sciences, Engineering, and Medicine. Dietary Reference Intakes for Dietary Fat: Total Fat and Fatty Acids by Life Stage Group. In: Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. 2006.
  9. Venn-Watson S. The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associated Diseases as Newly Identified Nutritional Pentadecanoic Acid (C15:0) Deficiency Syndrome. Metabolites. 2024;14:355. DOI 10.3390/metabo14070355.
  10. Venn-Watson S, Lumpkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Scientific Reports. 2020;10:8161. DOI 10.1038/s41598-020-64960-y.
  11. Venn-Watson SK, Butterworth CN. Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems. PLoS ONE. 2022;17:e0268778. DOI 10.1371/journal.pone.0268778.
  12. Venn-Watson S, Schork NJ. Pentadecanoic Acid (C15:0), an Essential Fatty Acid, Shares Clinically Relevant Cell-Based Activities with Leading Longevity-Enhancing Compounds. Nutrients. 2023;15:4607. DOI 10.3390/nu15214607.
  13. Fu WC, et al. Pentadecanoic acid promotes basal and insulin-stimulated glucose uptake in C2C12 myotubes. Food & Nutrition Research. 2021;65. DOI 10.29219/fnr.v65.4527.
  14. Venn-Watson S, Reiner J, Jensen ED. Pentadecanoylcarnitine is a newly discovered endocannabinoid with pleiotropic activities relevant to supporting physical and mental health. Scientific Reports. 2022;12:13717. DOI 10.1038/s41598-022-18266-w.
  15. Stallings VA, et al. Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis. International Journal of Clinical Pharmacology and Therapeutics. 2013;51:263–273. DOI 10.5414/CP201793. PMID 23357842.
  16. US Food and Drug Administration. Substances Added to Food: Pentadecanoic Acid. FDA food-substance inventory; accessed 14 July 2026.

Quality you can check

Every badge links to the document behind it: manufacturer certificates, certificates of analysis for all 26 actives, and our own promises about the formula.

Huazhen Biotechnology (Shenzhen) holds ISO 22000:2018 certificate 015FSMS2400550 and HACCP certificate 015HACCP2400460, both valid until 2 December 2027. These are manufacturer system papers, not a product certificate. The earlier papers 150FSMS2200001 and 150HACCP2200001 ended in March 2025 and are not shown as valid. Halal certificates cover raw materials from our suppliers; Geroprotect Essentials is not registered as a halal product. Food supplement. Read the current product label before use.

Bought from Geroprotect? Leave an honest review:Review us on TrustpilotReview us on GoogleReview on Amazon.aeReviews are optional and never rewarded. More about reviews.
Scroll to Top